Community Acquired Pneumonia – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Community Acquired Pneumonia – Pipeline Review, H1 2017’, provides an overview of the Community Acquired Pneumonia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Community Acquired Pneumonia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Community Acquired Pneumonia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Community Acquired Pneumonia

The report reviews pipeline therapeutics for Community Acquired Pneumonia by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Community Acquired Pneumonia therapeutics and enlists all their major and minor projects

The report assesses Community Acquired Pneumonia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Community Acquired Pneumonia

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Community Acquired Pneumonia

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Community Acquired Pneumonia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Aridis Pharmaceuticals LLC

BioAegis Therapeutics Inc

Biotest AG

InflaRx GmbH

ioGenetics Inc

Kyorin Pharmaceutical Co Ltd

Lascco SA

Melinta Therapeutics Inc

Merck & Co Inc

Nabriva Therapeutics AG

Paratek Pharmaceuticals Inc

TaiGen Biotechnology Co Ltd

Takeda Pharmaceutical Company Ltd

Tetraphase Pharmaceuticals Inc

TiGenix NV

Wockhardt Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Community Acquired Pneumonia - Overview

Community Acquired Pneumonia - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Community Acquired Pneumonia - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Community Acquired Pneumonia - Companies Involved in Therapeutics Development

Aridis Pharmaceuticals LLC

BioAegis Therapeutics Inc

Biotest AG

InflaRx GmbH

ioGenetics Inc

Kyorin Pharmaceutical Co Ltd

Lascco SA

Melinta Therapeutics Inc

Merck & Co Inc

Nabriva Therapeutics AG

Paratek Pharmaceuticals Inc

TaiGen Biotechnology Co Ltd

Takeda Pharmaceutical Company Ltd

Tetraphase Pharmaceuticals Inc

TiGenix NV

Wockhardt Ltd

Community Acquired Pneumonia - Drug Profiles

BT-086 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CAL-02 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ceftaroline fosamil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cx-611 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DBAF-301 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

delafloxacin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IFX-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lascufloxacin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lefamulin acetate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Nafithromycin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nemonoxacin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

omadacycline tosylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PneumoMab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Plasma Gelsolin Replacement for Community Acquired Pneumonia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

solithromycin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tosatoxumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TP-271 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Community Acquired Pneumonia - Dormant Projects

Community Acquired Pneumonia - Discontinued Products

Community Acquired Pneumonia - Product Development Milestones

Featured News & Press Releases

Feb 02, 2017: Nabriva Therapeutics Confirms No Sample Size Adjustment Required for LEAP 1 Phase 3 Trial of Lefamulin in Community Acquired Bacterial Pneumonia

Jan 18, 2017: Paratek Announces Completion of Enrollment in Omadacycline Phase 3 Community-Acquired Bacterial Pneumonia Study

Dec 29, 2016: Cempra Receives Complete Response Letter From FDA For Solithromycin NDAs

Dec 20, 2016: Nabriva Achieves 60% Randomization Target in LEAP 1 Phase 3 Trial in Community Acquired Bacterial Pneumonia

Dec 13, 2016: Paratek Advances Timing of Top-Line Data for Phase 3 Community Acquired Bacterial Pneumonia Study to the Second Quarter of 2017

Dec 05, 2016: Launch of Phase III clinical trial for the new macrolide antibiotic “T-4288” in Japan

Nov 04, 2016: FDA Advisory Committee Votes That Efficacy Results of Cempras Solithromycin Outweigh Risks for Community-Acquired Bacterial Pneumonia

Nov 01, 2016: Cempra Receives $10 Million Milestone Payment From Toyama Chemical (a Subsidiary of FUJIFILM Holdings Corporation) as Solithromycin Progresses to Phase 3 Studies in Japan

Oct 31, 2016: Nabriva Presents Research on Lefamulin at IDWeek 2016

Oct 20, 2016: Nabriva Announces Presentations at Upcoming IDWeek 2016

Aug 30, 2016: Cempra to Present Solithromycin at FDA Antimicrobial Drugs Advisory Committee Meeting on November 4, 2016

Aug 25, 2016: Cempras Pivotal Phase 3 SOLITAIRE-IV Study of IV to Oral Solithromycin Published in Clinical Infectious Diseases

Aug 23, 2016: Cempra Announces European Medicines Agency Validates MAA for Solithromycin for Treatment of CABP

Aug 11, 2016: Cempra Appoints Dr. David Zaccardelli to Board of Directors

Jul 05, 2016: Cempra Announces FDA Acceptance of Solithera New Drug Applications in the Treatment of Community-Acquired Bacterial Pneumonia

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Community Acquired Pneumonia, H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Community Acquired Pneumonia – Pipeline by Aridis Pharmaceuticals LLC, H1 2017

Community Acquired Pneumonia – Pipeline by BioAegis Therapeutics Inc, H1 2017

Community Acquired Pneumonia – Pipeline by Biotest AG, H1 2017

Community Acquired Pneumonia – Pipeline by InflaRx GmbH, H1 2017

Community Acquired Pneumonia – Pipeline by ioGenetics Inc, H1 2017

Community Acquired Pneumonia – Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2017

Community Acquired Pneumonia – Pipeline by Lascco SA, H1 2017

Community Acquired Pneumonia – Pipeline by Melinta Therapeutics Inc, H1 2017

Community Acquired Pneumonia – Pipeline by Merck & Co Inc, H1 2017

Community Acquired Pneumonia – Pipeline by Nabriva Therapeutics AG, H1 2017

Community Acquired Pneumonia – Pipeline by Paratek Pharmaceuticals Inc, H1 2017

Community Acquired Pneumonia – Pipeline by TaiGen Biotechnology Co Ltd, H1 2017

Community Acquired Pneumonia – Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017

Community Acquired Pneumonia – Pipeline by Tetraphase Pharmaceuticals Inc, H1 2017

Community Acquired Pneumonia – Pipeline by TiGenix NV, H1 2017

Community Acquired Pneumonia – Pipeline by Wockhardt Ltd, H1 2017

Community Acquired Pneumonia – Dormant Projects, H1 2017

Community Acquired Pneumonia – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Community Acquired Pneumonia, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports